Drug expansion: Pfizer ramps up obesity treatments with $4.9B Metsera deal; shares jump sharply
Drug expansion: Pfizer ramps up obesity treatments with $4.9B Metsera deal; shares jump sharply
Pfizer is significantly expanding its presence in the obesity treatment market by acquiring Metsera for $4.9 billion, offering a substantial premium per share. Metsera, while lacking marketed products, boasts several promising clinical programs. This strategic move reflects the surging demand for obesity treatments, currently dominated by Eli Lilly and Novo Nordisk.
Pfizer is significantly expanding its presence in the obesity treatment market by acquiring Metsera for $4.9 billion, offering a substantial premium per share. Metsera, while lacking marketed products, boasts several promising clinical programs. This strategic move reflects the surging demand for obesity treatments, currently dominated by Eli Lilly and Novo Nordisk.
Pfizer is significantly expanding its presence in the obesity treatment market by acquiring Metsera for $4.9 billion, offering a substantial premium per share. Metsera, while lacking marketed products, boasts several promising clinical programs. This strategic move reflects the surging demand for obesity treatments, currently dominated by Eli Lilly and Novo Nordisk. 
